AstraZeneca invests $2B in Summit Therapeutics for ADC trials

🌐 Investing.com (Cyprus) — 2026-09-29

AstraZeneca is investing $2 billion in Summit Therapeutics to support antibody-drug conjugate trials. The investment links the pharmaceutical companies’ resources to development of the clinical program.

Markets Deals Health AstraZeneca Summit Therapeutics investment antibody-drug conjugates clinical trials biopharmaceuticals

Read original source →

Crude price drop: FCCPC demands lower petrol prices
Punch Nigeria — 2026-11-10
Russian-Belarusian economic partnership expanding at good pace — Putin
TASS — 2026-11-10
Anthropic Launches New Workplace Software, Sending Microsoft Shares Tanking
The Information — 2026-11-10
LDO de 2027 é sancionada no Acre e prevê reajustes, concursos e estágio remunerado; VEJA
Globo — 2026-11-10
Khanna calls on Congress to ban sports prediction markets
The Hill — 2026-11-10
The stock market 'dodged a real bullet' — Cramer on Anthropic's new IPO valuation
CNBC — 2026-11-10

AstraZeneca invests $2B in Summit Therapeutics for ADC trials

AI Summary

Related Articles

Crude price drop: FCCPC demands lower petrol prices

Russian-Belarusian economic partnership expanding at good pace — Putin

Anthropic Launches New Workplace Software, Sending Microsoft Shares Tanking

LDO de 2027 é sancionada no Acre e prevê reajustes, concursos e estágio remunerado; VEJA

Khanna calls on Congress to ban sports prediction markets

The stock market 'dodged a real bullet' — Cramer on Anthropic's new IPO valuation